An observational study in Postoperative Pulmonary Complications, One Lung Ventilation and Ards, sponsored by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · Observational
This observational study investigates the relationship between the duration of single-lung ventilation (SLV) and the incidence of postoperative pulmonary complications (PPCs) such as pneumonia, pneumothorax, hemothorax, acute lung injury, and acute respiratory distress syndrome (ARDS) in adult patients undergoing thoracic surgery. A total of 134 patients aged 18-85 years, scheduled for thoracic surgery requiring SLV, will be monitored. Data including SLV duration, perioperative parameters, and postoperative pulmonary outcomes will be analyzed.
989 studies on the registry are indexed under Acute Lung Injury; 156 are open to participants now.
This study's planned enrollment of 134 is above the median of 100 across 367 observational studies indexed under Acute Lung Injury.
Browse Acute Lung Injury studies →Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital is the lead sponsor of 73 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of adult patients aged 18 to 85 years who are scheduled to undergo thoracic surgery at Etlik City Hospital and require OLV during the procedure. Patients will be included if they meet the eligibility criteria of being over 18 years old, undergoing thoracic surgery, receiving intraoperative OLV, and providing informed consent to participate in the study. Patients will be excluded if they are part of the pediatric age group, do not require OLV, or decline participation. A total of 134 eligible patients will be prospectively enrolled and followed for seven days postoperatively to assess the occurrence of pulmonary complications.
Age ≥18 years Undergoing thoracic surgery OLV planned during the procedure
Exclusion Criteria:
Pediatric patients Patients not requiring OLV Previous thoracic surgery
In this observational study, the naturally occurring duration of intraoperative single-lung ventilation (SLV) during thoracic surgery will be recorded. No intervention is applied or modified for research purposes. The exposure of interest is the total duration (in minutes) of SLV, which will be timed from initiation to termination during surgery. This variable will be analyzed in relation to postoperative pulmonary complications.
Postopertive Pulmonary Complications
Postoperative pulmonary complications (PPCs) are defined as respiratory events occurring within the first seven days following thoracic surgery, which negatively impact patient outcomes. In this study, PPCs include pneumonia, pneumothorax, hemothorax, acute lung injury, acute respiratory distress syndrome (ARDS), prolonged oxygen requirement, unplanned reintubation, and the need for non-invasive ventilation. These complications will be identified through clinical assessment, arterial blood gas analysis, and postoperative imaging such as chest X-rays. Each case will be evaluated using predefined diagnostic criteria to ensure consistency. The incidence of PPCs will be analyzed in relation to the duration of intraoperative single-lung ventilation.
Time frame: postoperative 7 days
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital